KVUE — Kenvue Inc.

The tape is balanced: Q2 2026 revenue grew 3.0% but organic growth was only 1.6%, adjusted gross margin fell 70bps, and adjusted EPS of $0.31 missed by a penny. The bigger driver is the KMB merger—approved by shareholders in January 2026 and targeted to close in Q4 2026—which gives the stock a floor but also caps upside until terms close. Analyst ratings are mostly Hold with a $19.50 average target.

Revenue has been a steady low-single-digit grower: $3.66B in Dec-2023, $3.90B in Mar-2026, and $3.96B in Jun-2026, with YoY growth recovering from -3.5% in Q3-2025 to +4.5% in Q1-2026 and +3.0% in Q2-2026. Operating margins were noisy in 2024 (Q2-2024 operating income was only $154M on one-offs), but recent quarters are healthier—TTM operating margin is 19.5% and TTM net margin is 10.8%. GAAP EPS in the last two reported quarters was $0.25 and $0.24, roughly in line with year-ago levels. This is not a growth story; it's a stable cash-generative staples franchise with occasional margin volatility.

As of 2026-08-27, the TTM P/E of 22.1x is flattered by one-off charges; on next-FY consensus EPS of $1.176, the forward P/E is about 16.3x. Price/sales of 2.39x is below the 5-year average of 2.84x, and the 4.39% dividend yield is supportive. On a forward basis the stock is fair to modestly cheap for a defensive staple, not a deep value.

At $19.20 the market is paying ~16x forward earnings for a company with 1.6% organic growth and 4.4% dividend yield. That is not pricing in a growth turnaround; it's pricing in stability plus deal completion. If the KMB deal closes at the expected terms, upside is likely capped near the deal value; if it breaks, the dividend and reasonable forward multiple provide a cushion but the stock could trade down toward the lower end of its range.

As of 2026-08-27, RSI-14 is 51.49—neutral, not overbought or oversold. Price sits just 0.2% above the 20-day SMA, 0.5% above the 50-day SMA, and 7.4% above the 200-day SMA. The stock is technically range-bound near the upper end of its 52-week range; there's no strong momentum signal in either direction, and a pullback toward the $18 area would be a more attractive entry.

• Tariffs and raw-material inflation are pressuring gross margin; adjusted gross margin fell 70bps in Q2 2026.
• High interest rates make the 4.39% dividend yield competitive versus cash, supporting the stock.
• Defensive-sector rotation favors consumer staples in a late-cycle, low-growth macro environment.
• Foreign exchange volatility is an ongoing headwind for a global consumer-health portfolio.
• International antitrust reviews (e.g., Australia) remain a final procedural hurdle for the KMB merger.

• Q4 2026 closing of the Kimberly-Clark combination and up to $2.1B of targeted annual cost synergies.
• Final international regulatory approvals for the KMB deal.
• Commercial ramp of newly approved Tylenol with Naproxen (3-year exclusivity) and Zyrtec Allergen Shield.
• Portfolio simplification—e.g., $284M sale of Brazil feminine care business to Essity—could unlock value.

• The KMB merger could be delayed, blocked, or closed on less-favorable terms, leaving KVUE in limbo.
• Persistent tariff, freight, or FX cost inflation could keep compressing margins and offset volume growth.
• Stagnant organic growth and private-label competition in OTC/self-care could make the high payout ratio unsustainable.
• The dividend payout is high (~88% of free cash flow), limiting financial flexibility while the deal is pending.

KVUE is a hold, not a compelling buy, at $19.20. The portfolio of trusted brands, 4.4% yield, and ~16x forward earnings make it a reasonable income vehicle, but the pending KMB transaction muddies the standalone story and top-line growth is weak. Wait for deal clarity or a lower entry price.

Applying a justified 17x forward P/E to next-FY consensus EPS of $1.176 gives $20.00; the multiple is modestly below the average staples multiple due to ~3% revenue growth and tariff/margin pressure, but supported by a 4.4% dividend yield, 19.5% operating margin, and low beta.